Lanreotide: A new therapeutic option in acromegaly

被引：0
|
作者：
Diez, JJ [1 ]
机构：
[1] HOSP LA PAZ,SERV ENDOCRINOL,MADRID,SPAIN
来源：
MEDICINA CLINICA | 1996年 / 107卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：257 / 269
页数：13
相关论文
共 50 条
  • [41] Micronized progesterone: A new therapeutic option
    Langer, RD
    INTERNATIONAL JOURNAL OF FERTILITY AND WOMENS MEDICINE, 1999, 44 (02): : 67 - 73
  • [42] Sorafenib as a new therapeutic option for Hepatoblastoma
    Dewerth, A.
    Eicher, C.
    Fuchs, J.
    Armeanu-Ebinger, S.
    KLINISCHE PADIATRIE, 2011, 223 (03): : 198 - 198
  • [43] Systematic Review of Octreotide Versus Lanreotide in the Treatment of Acromegaly Patients
    Nunes, Vania Santos
    Simoes Correa, Julia Martins
    Silva Puga, Maria Eduarda
    Koga Silva, Edina Mariko
    Boguszewski, Cesar Luiz
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [44] Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
    Shimatsu, Akira
    Teramoto, Akira
    Hizuka, Naomi
    Kitai, Kazuo
    Ramis, Joaquim
    Chihara, Kazuo
    ENDOCRINE JOURNAL, 2013, 60 (05) : 651 - 663
  • [45] Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
    Bernabeu, Ignacio
    Fajardo, Carmen
    Marazuela, Monica
    Cordido, Fernando
    Maria Venegas, Eva
    de Pablos-Velasco, Pedro
    Piedrola Maroto, Gonzalo
    Pilar Olvera, Maria
    Pavon de Paz, Isabel
    Carvalho, Davide
    Romero, Carme
    De la Cruz, Guillermo
    Alvarez Escola, Cristina
    ENDOCRINE, 2020, 70 (03) : 575 - 583
  • [46] An open, phase III study of lanreotide (Somatuline PR®) in the treatment of acromegaly
    Lin, JD
    Lee, ST
    Weng, HF
    ENDOCRINE JOURNAL, 1999, 46 (01) : 193 - 198
  • [47] Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
    Bevan, J. S.
    Newell-Price, J.
    Wass, J. A. H.
    Atkin, S. L.
    Bouloux, P. M.
    Chapman, J.
    Davis, J. R. E.
    Howlett, T. A.
    Randeva, H. S.
    Stewart, P. M.
    Viswanath, A.
    CLINICAL ENDOCRINOLOGY, 2008, 68 (03) : 343 - 349
  • [48] Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
    Ignacio Bernabéu
    Carmen Fajardo
    Mónica Marazuela
    Fernando Cordido
    Eva María Venegas
    Pedro de Pablos-Velasco
    Gonzalo Piedrola Maroto
    María Pilar Olvera
    Isabel Pavón de Paz
    Davide Carvalho
    Carme Romero
    Guillermo De la Cruz
    Cristina Álvarez Escolá
    Endocrine, 2020, 70 : 575 - 583
  • [49] Slow-release lanreotide and octreotide LAR in the medical therapy of acromegaly
    Giusti, M
    Sessarego, P
    Timossi, G
    Bocca, L
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (06) : 697 - 698
  • [50] Pituitary gland: Effect of lanreotide on postoperative health outcomes in patients with acromegaly
    Koch L.
    Nature Reviews Endocrinology, 2010, 6 (4) : 181 - 181
12345